Press Releases

Date Title and Summary View
Toggle Summary Oxford Immunotec Schedules First Quarter 2019 Earnings Release and Conference Call for May 9, 2019
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 25, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release first quarter 2019 financial results before the open of the market on
View HTML
Toggle Summary Oxford Immunotec Announces New Initiative to Bring the Benefit of Modern Tuberculosis Testing to the Russian Federation
OXFORD, United Kingdom and MARLBOROUGH, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced a new local production initiative to bring the benefits of the T-SPOT ® .
View HTML
Toggle Summary Oxford Immunotec Announces Chief Financial Officer Transition
OXFORD, United Kingdom and MARLBOROUGH, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that Richard Altieri, the Company’s Chief Financial Officer (CFO), will retire on April 30, 2019.
View HTML
Toggle Summary Oxford Immunotec Reports Fourth Quarter and Full Year 2018 Financial Results
OXFORD, United Kingdom and MARLBOROUGH, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the "Company"), a global, high-growth diagnostics company, today announced fourth quarter and full year 2018 financial results.
View HTML
Toggle Summary Oxford Immunotec to Participate in Two Upcoming Investor Conferences
OXFORD, United Kingdom and MARLBOROUGH, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, is scheduled to present at the following upcoming investor
View HTML
Toggle Summary Oxford Immunotec Schedules Fourth Quarter and Full Year 2018 Earnings Release and Conference Call for March 11, 2019
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release fourth quarter and full year 2018 financial results after the close of the
View HTML
Toggle Summary Oxford Immunotec Announces Board Approval of $100 Million Share Repurchase Program and Reaffirms Growth Expectations for Fourth Quarter 2018
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 06, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that its Board of Directors has approved a share purchase program, which would involve the purchase
View HTML
Toggle Summary Oxford Immunotec to Present at the 37th Annual J.P. Morgan Healthcare Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the 37th Annual J.P.
View HTML
Toggle Summary Oxford Immunotec Announces Regulatory Acceptance of T-Cell Select™ in China
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced regulatory acceptance of the T-Cell Select kit by the China Food and Drug Administration (CFDA).
View HTML
Toggle Summary Oxford Immunotec to Participate in Two Investor Conferences This Week
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, is scheduled to present at the following investor
View HTML